BENEFITS n The client was able to meet all internal expectations for their ascending dose study n Concentration-effect correlations were understood as soon as possible, thus protecting the well-being of the patients NEED n Top tier Pharma company required 24-hour analysis turnaround for multi- site patient ascending dose study from sample receipt to Quality Controlled (QC’d) bioanalytical data n Missing the timing window would result in delays to dosing in patient population n Delays may have complicated the goal of correlating safety, effect and pharmacokinetic data as soon as possible APPROACH n Coordinated with the courier company to understand the expected arrival time for the samples anticipated from three continents n Ensured that Celerion sample

Join for free to read